NCT00274443View on ClinicalTrials.gov

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 1, 2005

Primary Completion Date

June 1, 2007

Study Completion Date

June 1, 2007

Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

ABI-007 (Abraxane) and Carboplatin

ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks

Trial Locations (1)

Unknown

Study Sites in Russia, Saint Petersburg

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY